NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein shares split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has approved a stock repurchase program on Tuesday, September 19th 2017, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback programs are usually a sign that the company's leadership believes its stock is undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) released its earnings results on Tuesday, May, 8th. The company reported $0.95 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.92 by $0.03. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.18 billion. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. Henry Schein's quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.88 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.09.

19 Wall Street analysts have issued 12 month price targets for Henry Schein's stock. Their forecasts range from $73.00 to $102.00. On average, they anticipate Henry Schein's stock price to reach $81.50 in the next year. This suggests a possible upside of 10.5% from the stock's current price. View Analyst Ratings for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Henry Schein include Express Scripts (ESRX), Illumina (ILMN), FRESENIUS SE &/S (FSNUY), Humana (HUM), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ESSILOR Intl S/S (ESLOY), ASTELLAS PHARMA/ADR (ALPMY), Edwards Lifesciences (EW), Fresenius Medical Care AG & Co. (FMS) and Alexion Pharmaceuticals (ALXN).

Media coverage about HSIC stock has trended somewhat positive on Thursday, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Henry Schein earned a media sentiment score of 0.13 on Accern's scale. They also gave media headlines about the company an impact score of 46.34 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Henry Schein's stock is owned by many different of retail and institutional investors. Top institutional investors include Swedbank (1.33%), Fenimore Asset Management Inc. (0.36%), Riverbridge Partners LLC (0.27%), Bank of Montreal Can (0.24%), Port Capital LLC (0.14%) and Fisher Asset Management LLC (0.07%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Swedbank, Bank of Montreal Can, Neville Rodie & Shaw Inc., Riverbridge Partners LLC, Gateway Investment Advisers LLC, Carderock Capital Management Inc. and Laurel Grove Capital LLC. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Addenda Capital Inc., Xact Kapitalforvaltning AB, AMG National Trust Bank, Port Capital LLC, Addenda Capital Inc., State of Alaska Department of Revenue, Trust Co. of Oklahoma and DnB Asset Management AS. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $73.74.

Henry Schein has a market capitalization of $11.41 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]